ABXL
ABXLKey Statistics
About ABXL
Abraxas BioScience (ABXL) is a pioneering biopharmaceutical firm committed to addressing critical medical needs through the development of innovative therapies. With a focus on leveraging cutting-edge technologies in drug discovery, ABXL boasts a promising pipeline of proprietary drug candidates aimed at enhancing patient outcomes in areas of high unmet medical need. The company emphasizes scientific excellence and adheres to rigorous regulatory standards, fostering collaborations with leading academic institutions and industry stakeholders to accelerate the advancement of transformative healthcare solutions.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | — |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | 0 |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABXL and any ticker you trade — then tracks every position and per-strategy win rate.